A new company is developing malaria vaccines from mosquitoes.

Researchers of Sanaria Inc. are feeding mosquitoes human blood contaminated with the parasite Plasmodium falciparum

The World Health Organization has called for better prevention campaigns following the worst outbreak of dengue fever in Southeast Asia. The outbreak of this "bone-breaker" disease is seen in parts of Cambodia, Indonesia, Vietnam and Thailand.

A large number of the victims of this disease are children. The main symptoms are fever and crying from intense joint pain, a common symptom of the disease that spreads to humans by the Aedes aegypti mosquito, which feeds during the day

Plans are underway for Brazil's Ministry of Health to import a United States technology for producing anti-dengue-fever vaccine, as the government already assigned the Sao Paulo-based Butantan Institute to negotiate with U.S. researchers on this possible deal.

The agency's Secretary of Science Reynaldo Guimaraes said that the U.S. developed technology on anti-dengue-vaccine has shown "promising results". He however clarified that it would still take about three to four years to test its effectiveness

An experimental malaria vaccine tested in infants in Mozambique, Africa is safe and effective in babies, a new research has found. Scientists tested the drug in 214 infants, from ages 10-18 and compared the results to those who were not vaccinated.

The drug reduced the number of new infections in the infants by 65 percent, in a three month period, it was found. Investigators say the vaccine also reduced the number of infants who became critically ill by 35 percent

International researchers have successfully tested the effectiveness of a new anti-malaria vaccine on African babies. They will proceed to the final stage of the clinical trial of RTS,S in the hope that the vaccine will be approved by the medical community for use in protecting people against the deadly mosquito-borne disease.

According to Agence France-Presse, results of the latest clinical tests of the RTS,S were contained in a study released on Wednesday. The study, published in the British health journal The Lancet, said the tests involved the vaccination of 214 infants from malaria-infested villages in Mozambique with the vaccine developed by GlaxoSmithKline Biologicals of Belgium two decades ago and a standard hepatitis B vaccine called Engerix-B